ReviewRSC medicinal chemistry2025
The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.
Review in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Comprehensive Review of Antimicrobial Peptides and Smart Biomaterials in Chronic Wound Therapy: Overcoming Biofilms, Resistance, and Translational Barriers.International journal of molecular sciences · 2026Review
- Design of Multifunctional Bioactive Peptides for Potential Application in Food Packaging: A Machine-Learning-Integrated Optimization Framework.ACS omega · 2026Article
- Antimicrobial peptides-based strategies at the frontline in battling the escalating menace of methicillin-resistant Staphylococcus aureus biofilms.European journal of microbiology & immunology · 2026Review
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a mounting global health crisis demanding novel, sustainable therapeutic strategies beyond traditional antibiotics. Ultra-short cationic β-peptides have emerged as a promising class of synthetic antimicrobial foldamers with broad-spectrum activity, remarkable proteolytic stability, and low resistance potential. Designed through rational approaches, these 2-10 residue peptides leverage amphipathicity, structural rigidity, and electrostatic interactions to disrupt microbial membranes, biofilms, and even intracellular pathogens. Notably, they exhibit synergistic effects with conventional antibiotics and minimal toxicity to mammalian cells. Emerging
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.